Abstract. Colorectal cancer (CRC) ranks as the third-leading cause of cancer-associated mortalities in Taiwan. The expression of ribonucleotide reductase M2 (RRM2) and p53R2 is associated with tumoral malignancy and progression in several types of cancer. The aim of the present study was to determine the association of p53R2/RRM2 with the upstream expression of microRNA (miR)-211 and the association of expression levels of p53, APC and k-ras with clinical outcomes in patients with CRC. The study consisted of 192 tumor tissue samples obtained from patients with CRC. Immunohistochemistry and direct sequencing of DNA were performed to analyze p53R2/RRM2 protein expression and p53/APC/k-ras gene mutations in these samples. The expression level of miR-211 was detected by reverse transcription-quantitative polymerase chain reaction. The results showed that the expression of p53R2 was lower and that of RRM2 was higher in patients with lymph node metastasis, distant metastasis, and late-stage CRC compared with patients without lymph node metastasis, distant metastasis and early-stage CRC. A high expression of RRM2 in patients had a negative effect on overall survival (OS) and disease-free survival (DFS) in CRC. Positive expression of RRM2 was detected in tumor tissues, and expression associated with the presence of k-ras gene mutation. Furthermore, it was detected that the upstream miR-211 expression was negatively associated with RRM2 expression in tumor tissues of patients with CRC. miR-211 expression was associated with survival and tumoral recurrence in patients with k-ras mutations. The present authors suggest that the downregulation of miR-211 and overexpression of RRM2 in tumor tissues of patients with CRC could be used to predict metastases and disease prognosis, particularly in patients with k-ras gene mutations.
Introduction
Colorectal cancer (CRC) ranks as the third-leading cause of cancer-associated mortalities in Taiwan (1) . The majority of Taiwanese patients with CRC (60-70%) present with stage II-IV disease at initial diagnosis (2, 3) . Among newly diagnosed cases, ~20-25% of patients have advanced disease with distant metastases (2, 3) . Recurrence occurs in ~30% of patients with advanced CRC, even following curative resection (2) . Patients with stage I and II CRC have an 86-95% five-year survival rate, whereas those with stage III and IV metastatic diseases have five-year survival rates of ~67 and ~12%, respectively (3) . In a previous study by the present authors, it was reported that miR-211 regulates the expression of RRM2 in tumoral metastasis and recurrence in colorectal cancer patients with a k-ras gene mutation the genetic background of Taiwanese patients with CRC was different from that of Caucasian patients with CRC (4). In the study, ~33.8% of tumor tissues in Taiwanese patients with CRC contained Adenomatous polyposis coli (APC) mutations. This figure is close to that reported in Asia but significantly lower compared with the values reported in western countries (70-80%) (5) . Therefore, studies of the dynamic nature of molecular signatures in CRC are required to determine the prognosis of patients. Ribonucleotide reductase (RR) is a highly regulated rate-limiting enzyme that is used in the conversion of ribonucleoside diphosphate to 2'-deoxyribonucleoside diphosphate (6) , and it is essential for DNA synthesis (6, 7) . In humans, one large subunit (M1) and two small subunits (RRM2 and p53R2) of RR have been identified (6, 7) . Although the protein sequence of the two small RR subunits, p53R2 and RRM2, show 80% similarity, their biological function is markedly different (7) . Previous reports demonstrated that the regulation of RRM2 and p53R2 might play a critical role in the invasion potential of cancer cells and the establishment of the metastatic phenotype (8, 9) . Research also suggested that RRM2 might potentially serve as a biomarker for predicting aggressive CRC, with poor survivability and progression-free survival (10) . Inhibition of RR activity has been tested as a potential therapy in anticancer settings (11) . Therefore, the overexpression of RRM2 has an important role in the pathogenesis of CRC.
Research has suggested that microRNAs (miRNAs), which are small, noncoding RNAs, modulate gene expression by degrading mRNA and/or inhibiting protein translation (12) . The dysregulation of miRNA has been implicated in numerous processes during tumoral progression (12) . In previous reports by the present authors, it was demonstrated that different miRNAs were involved in the pathogenesis in CRC, depending on the presence or absence of an APC gene mutation (5, (13) (14) (15) . For example, miR-224 suppressed the migration of CRC cells by targeting cell division cycle 42 in patients with CRC and an APC gene mutation (13) . It was also demonstrated by the present authors that the downregulation of let-7a-5p in sera and tumor tissues of patients with CRC could be used to predict lymph node metastasis and disease prognosis (14) . In addition, the present authors demonstrated that let-7a appeared to regulate the expression of miR-21 (15) . miR-21 has oncogene-like activity and is highly expressed in several types of cancer (16) . In a recent study, it was also found that patients with APC mutations and high miR-21 expression had lower APC gene expression and exhibited poorer overall survival (OS) rates compared with patients with APC mutations and low miR-21 expression, APC wild-type and high miR-21 expression, and APC wild-type and high miR-21 expression (5). The same study demonstrated that the downregulation of APC gene expression was associated not only with expression of the APC gene mutation but also with upregulation of miR-21 (5) . Based on these findings, the present authors speculated that the expression of the p53, APC and k-ras genes may be associated with miRNA expression in patients with CRC.
The k-ras gene is a member of the ras gene family (H-, K-and N-ras) (17) . Oncogenic k-ras mutations have been detected in several types of cancer (e.g., lung, colon and pancreatic) (17) . Additionally, ~20-50% of primary colorectal tumors contain oncogenic k-ras mutations (18) . Recent clinical trials verified that the k-ras gene mutation was associated with cetuximab resistance in patients with metastatic CRC (19) . However, whether mutant k-ras genes affect survival rates, tumoral recurrence and drug resistance in patients with CRC and who receive adjuvant chemotherapy is unclear. Previous research identified a positive association between RRM2 and k-ras genes, showing that re-expressed k-ras genes in a HKe3 colon cancer cell line induced RRM2 expression (20) . Based on these findings, we suggest that the interaction of k-ras with RRM2 may play a role in survival rates and drug resistance in CRC patients.
In the present study, it was hypothesized that the downregulation of miR-211 would induce RRM2 expression and promote tumorigenesis in CRC and that the expression levels of miR-211, p53R2 and RRM2 may be used as biomarkers to predict clinical outcomes and tumoral recurrence in CRC. It was also hypothesized that p53/APC/k-ras gene mutations would result in overexpression of RRM2 and have a role in disease progression and clinical outcomes of patients with CRC. Therefore, the associations between miR-211, p53R2 and RRM2 gene expression and clinical outcomes in CRC patients with and without p53/APC/k-ras mutations were analyzed.
Patients and methods
Study population. CRC tumor tissue samples were collected from 192 non-selected patients who underwent surgical resection for CRC at the Department of Surgery, Taipei Medical University Hospital (Taipei, Taiwan) between December 2011 and December 2013 (14) . The acquisition of the samples and their subsequent examination were approved by the Institutional Review Board of Taipei Medical University (Taipei, Taiwan). Informed written consent was obtained from all the patients and/or guardians prior to the use of the resected specimens.
None of the participants had a previous history of cancer. The clinical stages and pathological features of primary tumors were defined according to the criteria of the American Joint Commission on Cancer (https://cancerstaging.org/referencestools/Pages/What-is-Cancer-Staging.aspx). A total of 33 of the 192 patients with stage IV disease and distant metastasis were enrolled in the present study, of which 5 had lung metastasis, 16 had liver metastasis, 9 had peritoneum metastasis and 3 had para-aortic lymph nodes metastasis. All of the patients had oligometastatic disease and had undergone surgery but not chemotherapy. Postoperative follow-up visits were scheduled every three months thereafter during the first two years, then every six months thereafter, or more frequently if needed. Survival and recurrence were followed up in all the patients in the present study.
The CRC tissues and paired non-tumor tissues from the aforementioned patients were obtained from the Tissue Bank of Taipei Medical University (Taipei. Taiwan) between December 2011 and December 2013. In the present study, a total 192 patients were enrolled, including 90 females and 102 males, age ranging from 40 to 90 years old. A pathologist confirmed that >95% of the cells were tumor cells based on H&E-stained frozen sections. The normal tissues were used as a control. These tissue samples were obtained from the same patient and were checked by a pathologist.
Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) -based detection of miR-211.
Total RNA was extracted from the tumor tissue samples or sera of the patients with CRC using TRIzol (Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA). The expression of mature miRNA was detected by a TaqMan miRNA assay (Applied Biosystems, Thermo Fisher Scientific, Inc; catalog no. 4427975; sequence; UUCCCUUUGUCAUCCUUCGCCU) and normalized relative to U6B using the 2 -ΔΔCq method (21) . All TaqMan PCRs were performed in triplicate. The PCR reaction was conducted with the following conditions: starting with 95˚C for 10 min, followed by 40 cycles of amplification (95˚C for 15 sec and 60˚C for 1 min). The definition of high and low expression of miR-211 was dependent on the mean value of the expression of these genes in the normal tissues of the patients. High expression was defined as expression levels higher than the mean expression in non-tumor tissues. Low expression was defined as expression levels lower than he mean expression in normal tissues. The mean expression level of miR-211 in normal colon tissue samples was 20.21±10.81. The PCR-based detection of miR-211 was conducted as described in a previous report by the present authors (14) .
Detection of p53R2 and RRM2 protein expression b y i m m u n o h i s t o c h e m i s t r y.
For m a l i n-f i xe d a nd paraffin-embedded specimens were sectioned at a thickness of 3 µm. All the sections were deparaffinized in xylene, sequentially rehydrated through serial dilutions of alcohol, and washed in phosphate-buffered saline. The sections used for p53R2 and RRM2 detection were immersed in a citrate buffer (pH 6.0) and heated in a microwave oven twice for 5 min. Mouse anti-p53R2 (catalog no. SC-137174) and RRM2 (catalog no. SC-81850) monoclonal antibodies (all 1:100; Santa Cruz Biotechnology, Inc., Dallas, TX, USA) were used as the primary antibodies. The conventional streptavidin peroxidase method (DAKO; Agilent Technologies, Inc., Santa Clara, CA, USA; LSAB Kit K675) was performed to develop signals according to the manufacturer's protocol and the cells were counter-stained with hematoxylin. The details of the protocol used have been described previously (22) . Negative controls that did not include the primary antibodies were also prepared. A total of three observers independently evaluated the results and scored the percentage of positive expression in the samples. In each specimen, the cells that positively stained for anti-p53R2 and RRM2 antibodies were recorded as a percentage (%) using a labeling index, and the measurements were calculated. The scores were as follows: 0, no positive staining; +, from 1 to 10% positive cells; ++, from 11 to 50% positive cells; and +++, >50% positive cells. Among the 192 CRC patients, 99 samples were negative for p53R2 protein expression. None of the patients were scored +, 57 were scored ++ and 36 were scored +++. For RRM2 protein expression, 96 patients were negative. None of the patients were scored +, 35 were scored ++ and 61 were +++. The scores of ++ and +++ were considered to represent high immunostaining, and scores of 0 and + were classified as low immunostaining.
Mutation analysis of APC, k-ras and p53 genes. Genomic DNA was prepared from 192 frozen CRC tissues using standard proteinase K digestion and phenol/chloroform extraction following homogenization. Mutations in the APC, p53 and k-ras genes were determined by direct sequencing of PCR products. The detailed protocol used has been described previously (23) . The target sequences were amplified in a 50 µl reaction mixture containing 20 pmol of each primer, 2.5 U Taq polymerase (Takara Bio, Inc., Otsu, Japan), 0.5 mmol/l dNTPs, 5 µl PCR reaction buffer and 1 µl genomic DNA as the template. Oligonucleotide primers were used to amplify the mutation cluster region of the APC, p53 and k-ras genes. A total of four sets of oligonucleotide primers were used for APC: Forward, 5'-CAG ACT TAT TGT GTA GAA GA-3' and reverse, Statistical analysis. All data were analyzed using the Statistical Package for the Social Sciences, software (version 13.0; SPSS, Inc., Chicago, IL, USA). A chi-square test (χ 2 test) was used to compare the association of p53R2 and RRM2 gene expression with clinical parameters in CRC. A total of two independent tests and k-independent nonparametric tests were used to compare the expression level of miR-211 in the presence of different clinical parameters in CRC. A probability value of P<0.05 was considered statistically significant. Kaplan-Meier survival curves were constructed for overall survival (OS) and disease-free survival (DFS), and the log-rank test was used to evaluate the differences in survival curves of patients with and without p53R2 and RRM2 expression. In the present study, survival was defined as the time from the date of the surgical intervention until 31st July 2016.
Results

RRM2/p53R2 expression is associated with tumoral metastasis in CRC.
The p53R2 gene was expressed in 93 of 192 (48.4%) patients, and hRRM2 was expressed in 96 of 192 (50.0%) patients. Both proteins were expressed in CRC tumor cells (Fig. 1) . As shown in Table I , the expression level of p53R2 was significantly lower in patients with distant metastasis and late-stage CRC compared with patients with no metastasis and early-stage CRC (M factor, distant metastasis, P=0.002; stage, P=0.008; Table I ). No additional associations were identified between p53R2 expression and other clinical parameters (Table I ). In addition, RRM2 expression was significantly higher in patients with lymph node metastasis and late-stage CRC compared with patients with no metastasis and early-stage CRC (N factor, lymph node metastasis, P=0.001; stage, P=0.001). No additional associations were detected between RRM2 and other clinical parameters (Table I) .
Effect of RRM2 and p53R2 expression on OS and DFS in CRC.
We hypothesized that the expression levels of p53R2 and RRM2 would contribute to tumoral progression and metastasis in CRC and that the expression of p53R2 and RRM2 would be associated with OS and DFS in CRC. As indicated by the results of the Kaplan-Meier analysis, p53R2 protein expression levels exhibited no association with OS or DFS in CRC (OS, P=0.488; DFS, P=0.915 for; Fig. 2) . However, the results of the Kaplan-Meier analysis demonstrated that RRM2 protein expression was associated with OS and DFS in patients with CRC (OS, P<0.0001; DFS, P=0.002; Fig. 2 ).
Patients with low RRM2 expression had longer OS and DFS compared patients with high RRM2 expression. Therefore, it is suggested that RRM2 expression has potential to be a prognostic and tumoral recurrence biomarker in patients with CRC.
RRM2 expression is associated with the k-ras gene mutation but not with p53/APC gene mutations in patients with CRC.
The associations between p53R2 and RRM2 expression and gene mutations (APC, p53 and k-ras) in patients with CRC were further analyzed. As indicated in Table II , the expression of p53R2 and RRM2 was not associated with APC or P53 gene mutations in tumors of patients with CRC. A positive association was observed between RRM2 protein expression and the k-ras gene mutation. However, there was no association between p53R2 expression and the k-ras mutation. In addition, the expression of RRM2 was higher in patients with the k-ras gene mutation compared with patients with wild-type k-ras (P=0.008; Table II) .
Effect of RRM2 expression on OS and DFS of patients with CRC according to k-ras status.
The results indicated that RRM2 expression was associated with the k-ras gene mutation. Therefore, it was hypothesized that the effects of RRM2 expression on OS or DFS in CRC would differ among patients, depending on the presence or absence of k-ras mutations. The results of the Kaplan-Meier analysis indicated that RRM2 expression was associated with clinical outcomes in patients with wild-type k-ras (P=0.001) and those with k-ras gene mutations (P=0.031) (all patients, P<0.0001; Fig. 3A-C) . The association between RRM2 expression and DFS in patients with and without k-ras mutations was also analyzed. The results revealed that hRRM2 expression was associated with overall DFS in patients with wild-type k-ras (P=0.009) and in those with the k-ras gene mutation (P=0.048) (all patients, P=0.002; Fig. 3D-F) . Therefore, it is suggested that RRM2 is not associated with the k-ras gene status but that RRM2 expression may have potential as a prognostic and recurrence marker in patients with CRC.
miR-211 expression negatively regulates RRM2 expression in patients with CRC and k-ras gene mutations.
The association of miR-211 with RRM2 expression in tumor tissue samples of patients with CRC was analyzed. The levels of miR-211 expression in tumor tissue samples from patients with CRC are illustrated in Fig. 4 . As indicated in Table III , the level of miR-211 was significantly negatively associated with RRM2 protein expression in patients with CRC and k-ras gene mutation (P<0.0001) but not in patients with CRC and wild-type k-ras gene (P=0.634). In addition, miR-211 expression was negatively associated with lymph node metastasis, distant metastasis, and cancer stage (all P<0.0001; Table III ). Patients with lymph node metastasis, distant metastasis, and late-stage disease had lower miR-211 expression compared with those with early-stage disease and without metastasis (Table III) .
Effect of miR-211 expression on OS and DFS in CRC.
It was hypothesized that miR-211 expression would be associated with clinical outcomes in patients with CRC, depending on the k-ras gene status of the patient. As indicated by the results of the Kaplan-Meier analysis, there was no association between OS and miR-211 expression in overall patients (P=0.488; Fig. 5A ) and patients with the wild-type k-ras gene (P=0.400; Fig. 5B ), but had effects in patients with k-ras gene mutations (P=0.003, Fig. 5C ). In addition, there was no association between miR-211 and DFS in all patients (P=0.255; Fig. 5D ) and patients with the wild-type k-ras gene (P=0.744; Fig. 5E ). However, miR-211 expression had effects on OS and DFS in patients with CRC and k-ras gene mutations ( Fig. 5C and F) , patients with high miR-211 expression having longer OS and DFS compared with patients with low miR-211 expression (OS, P=0.003; Fig. 5C ; DFS, P=0.004; Fig. 5F ).
The effects of miR-211 and RRM2 expression on OS and DFS were analyzed using the Kaplan-Meier method is presented in Fig. 6 . The results indicated that patients with CRC and high RRM2/low miR-211 expression and high RRM2/high miR-211 expression had significantly poorer OS (P<0.0001; Fig. 6A ) and DFS (P=0.015; Fig. 6B ) compared with those with low RRM2/high miR-211 expression and low RRM2/low miR-211 expression. A shown by the results of the Cox regression analysis, patients with late-stage disease and high RRM2 expression had a higher hazard ratio compared with patients with early-stage disease and low RRM2 expression (Table IV) . miR-211 expression and the presence of the k-ras mutation showed no significant different with overall survival of patients with CRC. These observations demonstrated that the expression of RRM2 in tumor tissues rather than the expression of miR-211 could be used as an independent biomarker to predict OS in CRC (Table IV) . It is suggested that a combination of miR-211 and RRM2 expression could be used as a prognostic and tumoral recurrence marker only in patients with CRC and the k-ras gene mutation.
Discussion
Previous reports demonstrated that patients with high RRM2 expression had poor prognoses and tumoral recurrence in several types of cancer, including hepatocellular cancer, prostate cancer, pancreatic cancer, CRC and lung cancer (9, 22, (24) (25) (26) . In the present study, it was detected that RRM2 expression in tumor tissues of patients with CRC and lymph node metastasis was significantly higher compared with patients without lymph Table III . Association of miR-211 expression levels and clinical parameters in tumor tissues of patients with colorectal cancer. node metastasis (Table I) . In addition, patients with high RRM2 expression in tumors had poor DFS (Fig. 2) . A previous study by Maftouh et al (27) on SUIT2-007 and SUIT2-028, subclones of a human pancreatic adenocarcinoma cell line (SUIT-2), reported that miR-211 targeted RRM2 and modulated its sensitivity to gemcitabine. In the present study, the expression of miR-211 was negatively associated with RRM2 expression in tumor tissues of patients with CRC and k-ras gene mutation (Table III) . Tumoral recurrence was lower in patients with CRC and k-ras mutation and high miR-211 expression compared with patients with the k-ras mutation and low miR-211 expression. Therefore, it was proposed that the level of RRM2 expression and upstream expression of miR-211 in tumor tissues of patients with CRC may be useful biomarkers to predict tumoral metastasis and tumoral recurrence, particularly in patients with the k-ras gene mutation. A previous study reported that RRM2 cooperated with a variety of oncogenes to promote cell transformation and tumorigenesis in cell model experiments (28) . In addition, human and mouse cell models demonstrated that RRM2 played a critical role in enhancing the invasive potential of tumor cells (28) (29) (30) (31) . In the present study, RRM2 expression was higher in lymph nodes invasion groups compared with the group without invasion (Table I) . Therefore, it was suggested that RRM2 expression in patients with CRC may be associated with increased metastasis of tumor cells.
miR-211 expression ---------------------------------------------------------------
As shown in a previous study, miR-211 modulated gemcitabine activity and inhibited the invasive ability of cancer cells by negatively regulating the expression of RRM2 (27) . The downregulation of let-7a and miR-211 was associated with the overexpression of k-ras in 9, 10-dimethyl-1,2-benz [a]anthracene-induced mouse skin tumorigenesis (32) . In the present study, the expression of miR-211 was negatively associated with RRM2 expression in tumor tissues of patients with CRC and k-ras mutation. Patients with low miR-211 expression and high RRM2 expression had poor DFS, particularly those with the k-ras mutation. Therefore, it was suggested that the k-ras gene mutation may be associated with downregulation of miR-211 and that this results in the overexpression of RRM2 and the induction of CRC tumorigenesis.
A meta-analysis indicated that the k-ras mutation was present in 1,364 of 4,687 (29.10%) patients with CRC (33) . This result is similar to the results found in the present study (25.5%; Table II) . Previous studies reported an association between k-ras gene mutation and clinicopathological characteristics (34) (35) (36) (37) . However, the association remains unclear, where some reports demonstrated that the k-ras gene mutation appeared to be associated with clinical outcomes, while other studies found no evidence to suggest that it could be used to predict clinical outcomes (34) (35) (36) (37) . The present study demonstrated that patients with low miR-211 expression had poor DFS, as did patients with the k-ras gene mutation. By contrast, the wild-type k-ras gene was not associated with poor DFS. A negative association was detected between RRM2 and miR-211 expression in patients with CRC and k-ras gene mutation (Table III) . These findings indicate that a combination of k-ras gene mutation and miR-211 and RRM2 expression, may be a useful biomarker to monitor tumoral recurrence in CRC. However, k-ras alone cannot be used as a biomarker.
In the present study, the IPA platform was used to investigate the associations between RRM2, p53R2, (RRM2B), k-ras and miR-211. The platform can reveal molecular interactions between these genes based on data recorded in the Ingenuity Knowledge Base. The Path Explore tool in IPA was used to identify interactions between the molecules (Fig. 7) . The following 13 interacting proteins were identified: Transcription regulators (n=4), enzymes (n=3), transporters (n=1) and proteins (n=5) with other functions. One of the proteins identified, Bcl2 is an apoptosis regulator, and it plays a central role by interacting with RRM2, k-ras and miR-211. The associations of these 13 target genes (Fig. 7) and the clinical application of these genes need to be examined in future studies.
In conclusion, it was detected that RRM2 and p53R2 protein expression was associated with lymph node and distant metastasis in CRC. Additionally, the expression level of RRM2 was regulated by miR-211. The protein expression of miR-211 and RRM2 but not that of p53R2 could be used to monitor metastasis, OS, and DFS in CRC, particularly in patients with CRC and k-ras gene mutation. The present authors propose that the activation of the k-ras gene may downregulate the expression of mir-211, resulting in RRM2 overexpression and the induction of tumoral recurrence in patients with CRC and k-ras gene mutation. 
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